

10/566193

IAP9 Rec'd PCT/PTO 30 JAN 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV710216014US, on the date shown below in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 30, 2006

Signature: *Staci V. Harris*

(Staci V. Harris)

Docket No.: 17243/003001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Melwyn Abreo et al.

Application No.: National Phase of
PCT/US2004/024657

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: PYRIDYL DERIVATIVES AND THEIR USE
AS THERAPEUTIC AGENTS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and

Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0591, under Order No. 17243/003001. A duplicate copy of this paper is enclosed.

Dated: January 30, 2006

Respectfully submitted,

By



T. Chyau Liang, Ph.D.
Registration No.: 48,885
OSHA · LIANG LLP
1221 McKinney St., Suite 2800
Houston, Texas 77010
(713) 228-8600
(713) 228-8778 (Fax)

IAP9 Rec'd PCT/PTO 30 JAN 2006

PTO/IB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Concurrently Herewith
		First Named Inventor	Melwyn Abreo
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet	1	of	1
		Attorney Docket Number	17243/003001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	WO-03/045921	06-05-2003	DAISON CO. LTD.	
	BB	EP-1180514	02-20-2002	Meiji Seika Kaisha, Ltd.	
	BC	WO-02/012778	12-27-2002	Iwata Masahiro	
	BD	EP-1396487	03-10-2004	Yamanouchi Pharma Co. Ltd.	
	BE	WO-02/088093	11-07-2002	Abbott Lab	
	BF	WO-02/081453	10-17-2004	Ou Khan, Boubia Benaissa	
	BG	WO-01/96327	12-20-2001	Dodic Nerina;	
	BH	WO-01/68619	09-20-2001	Warmus Joseph Scott	
	BI	EP-1243268	09-25-2002	Nippon Shinyaku Co. Ltd.	
	BJ	WO-88/08424	11-03-1988	UpJohn Co.	
	BK	WO-88/07527	10-06-1988	UpJohn Co.	
	BL	EP-0385350	09-05-1990	Nissin Flour Milling Co.	
	BM	WO-01/62954	08-30-2001	Univ. British Columbia	
	BN	WO-03/075929	09-18-2003	Meerpoet Lieven	
	BO	WO-03/066604	08-14-2003	Boehringer Ingelheim Int	
	BP	WO-03/091247	11-06-2003	Chen Yiyuan	
	BQ	WO-2004/035549	04-29-2004	Ogyanov Vassil	
	BR	JP 2004-203871	07-23-2004	Yamanouchi Pharm. Co. Ltd.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the citation, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	CA	International Search Report, PCTUS2004/024657, 2/15/2005.		
	CB	Patent Abstracts of Japan, vol. 2003, no. 12, December 5, 2003 (1 page)		
	CC	Jacobsen, Jon E. et al. "2-Aminomethyl) chromans that inhibit iron-dependent lipid peroxidation and protect against central nervous system trauma and ischemia"; Journal of Medicinal Chemistry, vol. 35, no. 23, 1992, pages 4464-4472.		
	CD	Jacobsen, E. J. et al. "Novel 21 Aminosteroids that inhibit iron-dependent lipid peroxidation and protect against central nervous system trauma"; Journal of Medicinal Chemistry, vol. 33, no. 4, 1990, pages 1145-1151.		
	CE	Chemical Abstracts Service, Columbus, Ohio, US; DN: 87:201475, 1977, Thunus: "Synthesis and pharmacological" p. 1-3.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 1346/5	/Noble Jarrell/ (04/18/2008)	Date Considered
------------------------------	------------------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./ (04/18/2008)